HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB‐C/EBPβ Axis

Inhibition of pathological cardiac hypertrophy is recognized as an important therapeutic strategy for heart failure, although effective targets are still lacking in clinical practice. Homeodomain interacting protein kinase 1 (HIPK1) is a conserved serine/threonine kinase that can respond to differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bei, Yihua, Zhu, Yujiao, Wei, Meng, Yin, Mingming, Li, Lin, Chen, Chen, Huang, Zhenzhen, Liang, Xuchun, Gao, Juan, Yao, Jianhua, van der Kraak, Petra H., Vink, Aryan, Lei, Zhiyong, Dai, Yuxiang, Chen, Huihua, Liang, Yueyang, Sluijter, Joost PG, Xiao, Junjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288234/
https://www.ncbi.nlm.nih.gov/pubmed/37098980
http://dx.doi.org/10.1002/advs.202300585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288234/
https://www.ncbi.nlm.nih.gov/pubmed/37098980
http://dx.doi.org/10.1002/advs.202300585

Ejemplares similares